{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:08:07Z","timestamp":1784092087022,"version":"3.55.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82272182"],"award-info":[{"award-number":["No. 82272182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Therapy resistance and relapse remain major obstacles in the treatment of lymphoid malignancies. While the cancer stem cell (CSC) hypothesis has long served as a conceptual framework for understanding chemoresistance, evidence for its direct applicability in lymphoid malignancies is still limited. More recently, drug-tolerant persister (DTP) cells have emerged as an important model for exploring resistance mechanisms, offering complementary perspectives beyond the CSC paradigm. In this review, we summarize recent advances in the study of DTP cells in lymphoid malignancies, including their progression to drug-tolerant expanded persister (DTEP) cells. We discuss experimental models and methodological approaches for investigating DTP cells, as well as the underlying mechanisms of persistence and resistance, which encompass gene-regulatory changes, cell surface remodeling, and immune evasion strategies. Finally, we highlight potential therapeutic avenues such as targeting glycosylation-related pathways, exploiting immunotherapeutic glycopeptide targets, and implementing rational combination regimens. By integrating insights from DTP biology, this review aims to broaden current theories to therapy resistance in lymphoid malignancies and inform the development of innovative treatment strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1713277","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:58Z","timestamp":1784090878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Meng","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","first-page":"535-546(2017)","article-title":"Understanding the new WHO classification of lymphoid Malignancies: why it\u2019s important and how it will affect practice","volume-title":"American Society of Clinical Oncology Educational Book American Society of Clinical Oncology Annual Meeting","author":"Jaffe","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13423","article-title":"Towards precision medicine in lymphoid Malignancies","volume":"292","author":"B\u00fchler","year":"2022","journal-title":"J Internal Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid Malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid Malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3597","article-title":"Unravelling cancer stem cell potential","volume":"13","author":"Beck","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2824","article-title":"Cancer stem cells and self-renewal","volume":"16","author":"O'Brien","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160232","article-title":"Challenging perspectives on the cellular origins of lymphoma","volume":"6","author":"Malcolm","year":"2016","journal-title":"Open Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008854","article-title":"Mature lymphoid Malignancies: origin, stem cells, and chronicity","volume":"1","author":"Husby","year":"2017","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3324\/haematol.2009.013318","article-title":"Lymphoma stem cells: enough evidence to support their existence","volume":"95","author":"Martinez-Climent","year":"2010","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5045\/kjh.2011.46.4.211","article-title":"Lymphoma stem cells: A step toward a new therapeutic target","volume":"46","author":"Kim","year":"2011","journal-title":"Korean J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.lungcan.2024.107885","article-title":"Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer","volume":"194","author":"Izumi","year":"2024","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14316","article-title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer","volume":"111","author":"Kawakami","year":"2020","journal-title":"Cancer Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.drup.2023.101007","article-title":"Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells","volume":"71","author":"Szeb\u00e9nyi","year":"2023","journal-title":"Drug Resistance Updates"},{"key":"B19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41419-024-06674-x","article-title":"ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC","volume":"15","author":"B\u00f6pple","year":"2024","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00402-0","article-title":"Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy","volume":"3","author":"\u00c1lvarez-Varela","year":"2022","journal-title":"Nat Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1586552","article-title":"Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment","volume":"12","author":"Li","year":"2025","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"key":"B26","first-page":"2023.02.28.530540","article-title":"Drug-tolerant persister B-cell precursor acute lymphoblastic leukemia cells","volume-title":"Biorxiv: The Preprint Server for Biology","author":"Zhang","year":"2023"},{"key":"B27","first-page":"2024.08.22.609211","article-title":"Remodelling of the glycome of B-cell precursor acute lymphoblastic leukemia cells developing drug-tolerance","volume-title":"Biorxiv: The Preprint Server for Biology","author":"Oliveira","year":"2024"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00219-3","article-title":"Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia","volume":"2","author":"Turati","year":"2021","journal-title":"Nat Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105013","article-title":"Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters","volume":"25","author":"van Gils","year":"2022","journal-title":"iScience"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1182\/blood-2023-178995","article-title":"AML drug tolerant persister (DTP) cells survive chemotherapy by transiently altering cellular lipidomics to increase plasma membrane rigidity, but also increases sensitivity to immune cell killing","volume":"142","author":"Morgenstern","year":"2023","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0603-3","article-title":"A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy","volume":"562","author":"S\u00e1nchez-Dan\u00e9s","year":"2018","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An embryonic diapause-like adaptation with suppressed myc activity enables tumor treatment persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01047-6","article-title":"H3K27me3 conditions chemotolerance in triple-negative breast cancer","volume":"54","author":"Marsolier","year":"2022","journal-title":"Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0653","article-title":"Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","first-page":"eaav0936","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114903","article-title":"Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.can-22-2370","article-title":"PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation","volume":"74","author":"Raha","year":"2014","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-29316-3_99","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1038\/s41467-019-13360-6","article-title":"An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells","volume":"10","author":"Shen","year":"2019","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin \u03b21\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-017-0435-1","article-title":"Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance","volume":"12","author":"Hammerlindl","year":"2018","journal-title":"J Cell Commun Signaling"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"key":"B51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1016\/j.jtho.2017.06.019","article-title":"Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC","volume":"9","author":"Arasada","year":"2018","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","article-title":"NF-\u03baB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer","volume":"11","author":"Blakely","year":"2015","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41698-022-00337-w","article-title":"The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells","volume":"6","author":"Criscione","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286018","article-title":"Acute myeloid leukemia drug tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing","volume":"110","author":"Morgenstern","year":"2024","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh261","article-title":"Modeling metastasis in vivo","volume":"26","author":"Khanna","year":"2005","journal-title":"Carcinogenesis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1771061","article-title":"Drug-tolerant persister cells in cancer: a scoping review of definitions, models, and molecular mechanisms","volume":"16","author":"Lopez-Gonzalez","year":"2026","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215154","article-title":"Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq","volume":"14","author":"Giannuzzi","year":"2019","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.881345","article-title":"Single-cell RNA-seq and bulk RNA-seq reveal intratumoral heterogeneity and tumor microenvironment characteristics in diffuse large B-cell lymphoma","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Genet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e20708","DOI":"10.1016\/j.heliyon.2023.e20708","article-title":"A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing data","volume":"9","author":"Du","year":"2023","journal-title":"Heliyon"},{"key":"B63","doi-asserted-by":"publisher","first-page":"167693","DOI":"10.1016\/j.bbadis.2025.167693","article-title":"Single-cell RNA sequencing and machine learning provide candidate drugs against drug-tolerant persister cells in colorectal cancer","volume":"1871","author":"Nojima","year":"2025","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0073","article-title":"Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.3390\/cells10113058","article-title":"Integrated N-and O-glycomics of acute myeloid leukemia (AML) cell lines","volume":"10","author":"Bl\u00f6chl","year":"2021","journal-title":"Cells"},{"key":"B66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-023-00981-0","article-title":"Transcriptionally imprinted glycomic signatures of acute myeloid leukemia","volume":"13","author":"Bl\u00f6chl","year":"2023","journal-title":"Cell Biosci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.21037\/tcr-23-1146","article-title":"Application and progress of CRISPR\/Cas9 gene editing in B-cell lymphoma: a narrative review","volume":"13","author":"Jin","year":"2024","journal-title":"Trans Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006232","article-title":"CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000909","article-title":"Robust CRISPR-Cas9 genetic editing of primary chronic lymphocytic leukemia and mantle cell lymphoma cells","volume":"7","author":"Mateos-Jaimez","year":"2023","journal-title":"HemaSphere"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"key":"B71","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers14040860","article-title":"Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas","volume":"14","author":"Profit\u00f3s-Pelej\u00e0","year":"2022","journal-title":"Cancers"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1339620","article-title":"B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Schmid","year":"2024","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01014-z","article-title":"Histone modifications in drug-resistant cancers: from a cancer stem cell and immune evasion perspective","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204957","article-title":"Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers","volume":"15","author":"Xu","year":"2023","journal-title":"Cancers"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell\u2013like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","article-title":"Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell Malignancies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/life12020256","article-title":"BH3-only proteins Noxa and Puma are key regulators of induced apoptosis","volume":"12","author":"Roufayel","year":"2022","journal-title":"Life"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073169","article-title":"Knockdown of human TCF4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation","volume":"8","author":"Forrest","year":"2013","journal-title":"PloS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e45617","DOI":"10.1371\/journal.pone.0045617","article-title":"Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells","volume":"7","author":"Xie","year":"2012"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108229","article-title":"Targeting CDK7 in oncology: The avenue forward","volume":"240","author":"Li","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020254","article-title":"Starving multiple myeloma cells via CDK7 inhibition","volume":"141","author":"Sacco","year":"2023","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2131408","article-title":"IFN-\u03b3 enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway","volume":"64","author":"Shao","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109978","article-title":"BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells","volume":"361","author":"Chiou","year":"2022","journal-title":"Chem Biol Interact"},{"key":"B88","doi-asserted-by":"publisher","first-page":"131511","DOI":"10.1016\/j.ijbiomac.2024.131511","article-title":"Exploring glycans as vital biological macromolecules: A comprehensive review of advancements in biomedical frontiers","volume":"268","author":"Arora","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cellsig.2017.08.002","article-title":"The role of G protein-coupled receptors in lymphoid Malignancies","volume":"39","author":"Nugent","year":"2017","journal-title":"Cell Signal"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030645","article-title":"Targeting tumor glycans for cancer therapy: successes, limitations, and perspectives","volume":"14","author":"Berois","year":"2022","journal-title":"Cancers"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00364","article-title":"Multiple roles of glycans in hematological Malignancies","volume":"8","author":"Pang","year":"2018","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216796120","article-title":"O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation","volume":"120","author":"Zhu","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.7150\/thno.65398","article-title":"Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia","volume":"11","author":"Oliveira","year":"2021","journal-title":"Theranostics"},{"key":"B95","doi-asserted-by":"publisher","first-page":"343884","DOI":"10.1016\/j.aca.2025.343884","article-title":"Stable isotope tracing reveals glucose metabolism characteristics of drug-resistant B-cell acute lymphoblastic leukemia","volume":"1352","author":"Hu","year":"2025","journal-title":"Anal Chim Acta"},{"key":"B96","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13402-023-00770-4","article-title":"Aberrant N-glycosylation in cancer: MGAT5 and \u03b21, 6-GlcNAc branched N-glycans as critical regulators of tumor development and progression","volume":"46","author":"de-Souza-Ferreira","year":"2023","journal-title":"Cell Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2023.108894","article-title":"Glycoproteomic analysis of regulatory effects of bisecting N-glycans on N-glycan biosynthesis and protein expressions in human HK-2 cells","volume":"531","author":"Dang","year":"2023","journal-title":"Carbohydr Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00511","article-title":"The essential functions and detection of bisecting GlcNAc in cell biology","volume":"8","author":"Chen","year":"2020","journal-title":"Front Chem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43865","article-title":"MGAT3-mediated glycosylation of tetraspanin CD82 at asparagine 157 suppresses ovarian cancer metastasis by inhibiting the integrin signaling pathway","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"B100","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1061177","article-title":"Cancer cell associated glycans as targets for immunotherapy","volume":"5","author":"Vankemmelbeke","year":"2016","journal-title":"Oncoimmunology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215376120","article-title":"MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint","volume":"120","author":"Smith","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2022.12.010","article-title":"Drug-tolerant persister cells after EGFR tyrosine kinase inhibitor treatment: their origin and the influences from the tumor microenvironment","volume":"18","author":"Ebi","year":"2023","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-025-01656-8","article-title":"Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms","author":"Davern","year":"2025","journal-title":"Cell Death Differ"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e135038","DOI":"10.1172\/jci135038","article-title":"Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade","volume":"131","author":"Sehgal","year":"2021","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-1693","article-title":"The activity of EGFR CAR NK and CAR T cells against EGFR inhibitor\u2013resistant NSCLC and drug-tolerant persister cells","volume":"31","author":"Yang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2008.05.002","article-title":"T and B lymphocyte differentiation from hematopoietic stem cell","volume":"20","author":"Lai","year":"2008","journal-title":"Semin Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self\u2010renewal versus differentiation","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Reviews: Syst Biol Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791517","article-title":"Differentiation-based model of hematopoietic stem cell functions and lineage pathways","volume":"132","author":"H\u00f6fer","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2174\/1875692116666180821095434","article-title":"Individualized cancer therapy, future approaches","volume":"16","author":"Lu","year":"2018","journal-title":"Curr Pharmacogenomics Pers Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.03.011","article-title":"Stem cells and cancer: two faces of eve","volume":"124","author":"Clarke","year":"2006","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"crossref","DOI":"10.1101\/sqb.2005.70.057","article-title":"Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors","author":"Pardal","year":"2005"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062081","article-title":"Drug resistance in non-Hodgkin lymphomas","volume":"21","author":"Klener","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1740281","article-title":"Drug-tolerant persister cells: the deadly survivors in hematological Malignancies","volume":"17","author":"Ma","year":"2026","journal-title":"Front Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050779","article-title":"Drug-tolerant persister cells and tumor dormancy in NSCLC: a new frontier in overcoming therapeutic resistance","volume":"18","author":"Lalla","year":"2026","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123553","article-title":"Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance","volume":"12","author":"Berendsen","year":"2020","journal-title":"Cancers"},{"key":"B117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for Malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041711","article-title":"Antibody therapy for patients with lymphoid Malignancies: past and present","volume":"26","author":"Naman","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100822","article-title":"Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma","volume":"61","author":"Pi","year":"2022","journal-title":"Drug Resistance Updates"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010140","article-title":"Amino acid metabolism in cancer drug resistance","volume":"11","author":"Yoo","year":"2022","journal-title":"Cells"},{"key":"B121","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-022-01313-4","article-title":"Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1389713","article-title":"Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression","volume":"14","author":"Tian","year":"2024","journal-title":"Front Oncol"},{"key":"B123","article-title":"Enzyme assay of \u03b21, 3-N-acetylgalactosaminyltransferase 2 (B3GALNT2)","volume-title":"Glycoscience Protocols (Glycopodv2)[Internet]","author":"Angata","year":"2022"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00912","article-title":"Altered N-linked glycosylation in follicular lymphoma and chronic lymphocytic leukemia: involvement in pathogenesis and potential therapeutic targeting","volume":"8","author":"Hollander","year":"2017","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-1401","article-title":"Targeting N-linked glycosylation for the therapy of aggressive lymphomas","volume":"13","author":"Scheich","year":"2023","journal-title":"Cancer Discov"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772304","article-title":"O-GlcNAcylation in chronic lymphocytic leukemia and other blood cancers","volume":"12","author":"Spaner","year":"2021","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/15216540701736285","article-title":"Role of the MRP1\/ABCC1 multidrug transporter protein in cancer","volume":"59","author":"Munoz","year":"2007","journal-title":"IUBMB Life"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2014.901348","article-title":"Importance of ABCC1 for cancer therapy and prognosis","volume":"46","author":"Kunicka","year":"2014","journal-title":"Drug Metab Rev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-95309-0_1895","article-title":"Non\u2010muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma","volume":"37","author":"Lamant","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00880-2","article-title":"Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt\u2013\u03b2-catenin\u2013STAT3 signaling","volume":"29","author":"Hu","year":"2022","journal-title":"Cell Death Differ"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14290","article-title":"THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors","volume":"8","author":"Cayrol","year":"2017","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41419-019-1831-7","article-title":"CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2\/BCL-XL inhibitor ABT-263","volume":"10","author":"Huang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000740","article-title":"Metabolic regulation of hematopoietic stem cells","volume":"6","author":"Morganti","year":"2022","journal-title":"Hemasphere"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.12.005","article-title":"Deciphering the metabolic heterogeneity of hematopoietic stem cells with single-cell resolution","volume":"36","author":"Cao","year":"2024","journal-title":"Cell Metab"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01102-2","article-title":"Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma","volume":"24","author":"Wu","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011920","article-title":"MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial","volume":"8","author":"Jerkeman","year":"2024","journal-title":"Blood Adv"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430070","article-title":"Minimal residual disease detection in lymphoma: methods, procedures and clinical significance","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1038\/s41467-024-47012-1","article-title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B140","article-title":"Mechanism of Transcriptional control of oncogenic transcription factor fusions in tumor development","volume-title":"Vanderbilt University","author":"Zhang","year":"2022"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01285-3","article-title":"Treatment resistance in diffuse large B-cell lymphoma","volume":"35","author":"He","year":"2021","journal-title":"Leukemia"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non\u2010Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cancers9110146","article-title":"Advances in Precision Medicine: Tailoring Individualized Therapies","volume":"9","author":"Matchett","year":"2017","journal-title":"Cancers"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020242","article-title":"Personalized medicine: recent progress in cancer therapy","volume":"13","author":"Hoeben","year":"2021","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:48:15Z","timestamp":1784090895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":144,"alternative-id":["10.3389\/fonc.2026.1713277"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1713277","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1713277"}}